232 related articles for article (PubMed ID: 31043459)
21. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.
Wu JD; Cui YJ; Zhou YG; Tang LQ; Zhang CM; Liu ZP
Invest New Drugs; 2020 Feb; 38(1):29-38. PubMed ID: 30887253
[TBL] [Abstract][Full Text] [Related]
22. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
Meng F; Cai X; Duan J; Matteucci MG; Hart CP
Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
[TBL] [Abstract][Full Text] [Related]
23. Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; Chen H; Wu Z; Yang J; White SW; Miller DD; Li W
J Med Chem; 2018 Sep; 61(17):7877-7891. PubMed ID: 30122035
[TBL] [Abstract][Full Text] [Related]
24. Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.
Gilson P; Josa-Prado F; Beauvineau C; Naud-Martin D; Vanwonterghem L; Mahuteau-Betzer F; Moreno A; Falson P; Lafanechère L; Frachet V; Coll JL; Fernando Díaz J; Hurbin A; Busser B
Sci Rep; 2017 Aug; 7(1):10209. PubMed ID: 28860487
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities.
Ren Y; Wang Y; Li G; Zhang Z; Ma L; Cheng B; Chen J
J Med Chem; 2021 Apr; 64(8):4498-4515. PubMed ID: 33788562
[TBL] [Abstract][Full Text] [Related]
26. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
27. X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.
Banerjee S; Mahmud F; Deng S; Ma L; Yun MK; Fakayode SO; Arnst KE; Yang L; Chen H; Wu Z; Lukka PB; Parmar K; Meibohm B; White SW; Wang Y; Li W; Miller DD
J Med Chem; 2021 Sep; 64(17):13072-13095. PubMed ID: 34406768
[TBL] [Abstract][Full Text] [Related]
28. Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.
Chen H; Deng S; Wang Y; Albadari N; Kumar G; Ma D; Li W; White SW; Miller DD; Li W
J Med Chem; 2020 Jan; 63(2):827-846. PubMed ID: 31860298
[TBL] [Abstract][Full Text] [Related]
29. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
30. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel 2-phenyl-imidazo[1,2-a]pyridine analogues targeting tubulin polymerization as antiproliferative agents.
An W; Wang W; Yu T; Zhang Y; Miao Z; Meng T; Shen J
Eur J Med Chem; 2016 Apr; 112():367-372. PubMed ID: 26927488
[TBL] [Abstract][Full Text] [Related]
32. Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.
Cheng B; Zhu G; Meng L; Wu G; Chen Q; Ma S
Eur J Med Chem; 2022 Jan; 228():113930. PubMed ID: 34794817
[TBL] [Abstract][Full Text] [Related]
33. X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors.
Arnst KE; Banerjee S; Wang Y; Chen H; Li Y; Yang L; Li W; Miller DD; Li W
ACS Chem Biol; 2019 Dec; 14(12):2810-2821. PubMed ID: 31714738
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain.
Li W; Yin Y; Shuai W; Xu F; Yao H; Liu J; Cheng K; Xu J; Zhu Z; Xu S
Bioorg Chem; 2019 Mar; 83():380-390. PubMed ID: 30408650
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin.
Gao F; Liang Y; Zhou P; Cheng J; Ding K; Wang Y
Eur J Med Chem; 2019 Sep; 178():177-194. PubMed ID: 31185410
[TBL] [Abstract][Full Text] [Related]
36. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
37. Ligand- and structural-based discovery of potential small molecules that target the colchicine site of tubulin for cancer treatment.
Guo Q; Zhang H; Deng Y; Zhai S; Jiang Z; Zhu D; Wang L
Eur J Med Chem; 2020 Jun; 196():112328. PubMed ID: 32320841
[TBL] [Abstract][Full Text] [Related]
38. A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.
Ning N; Yu Y; Wu M; Zhang R; Zhang T; Zhu C; Huang L; Yun CH; Benes CH; Zhang J; Deng X; Chen Q; Ren R
Cancer Res; 2018 Oct; 78(20):5949-5957. PubMed ID: 30135190
[TBL] [Abstract][Full Text] [Related]
39. 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
Lin MS; Hong TM; Chou TH; Yang SC; Chung WC; Weng CW; Tsai ML; Cheng TR; Chen JJW; Lee TC; Wong CH; Chein RJ; Yang PC
Eur J Med Chem; 2019 Nov; 181():111584. PubMed ID: 31419740
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment.
Bariwal J; Kumar V; Chen H; Bhattarai RS; Peng Y; Li W; Mahato RI
J Control Release; 2019 Sep; 309():231-243. PubMed ID: 31330213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
